[go: up one dir, main page]

KR900017577A - 폴리아민 유도체를 사용하여 세포- 중재의 면역성을 상승시키는 방법 - Google Patents

폴리아민 유도체를 사용하여 세포- 중재의 면역성을 상승시키는 방법 Download PDF

Info

Publication number
KR900017577A
KR900017577A KR1019900007406A KR900007406A KR900017577A KR 900017577 A KR900017577 A KR 900017577A KR 1019900007406 A KR1019900007406 A KR 1019900007406A KR 900007406 A KR900007406 A KR 900007406A KR 900017577 A KR900017577 A KR 900017577A
Authority
KR
South Korea
Prior art keywords
saturated
integer
alkyl
cell
elevated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1019900007406A
Other languages
English (en)
Inventor
린 바우린 테리
자야 프라카쉬 넬리쿤자
Original Assignee
게리 디. 스트리트
메렐 다우 파마슈티칼즈 인코오퍼레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게리 디. 스트리트, 메렐 다우 파마슈티칼즈 인코오퍼레이티드 filed Critical 게리 디. 스트리트
Publication of KR900017577A publication Critical patent/KR900017577A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

내용 없음

Description

폴리아민 유도체를 사용하여 세포-중재의 면역성을 상승시키는 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (16)

  1. 하기 일반식(I)또는 이의 약제학적으로 허용되는 염의 효과 세포-중재의 면역성 상승 유효량을 이를 요하는 환자에 투여함을 특징으로 하여, 세표-중재의 면역성을 상승시키는 방법.
  3. 상기식에서, m은 3내지 12의 정수이고, z는 직쇄 또는 측쇄 배위의 포화 C2-C6알킬렌부위이며, R그룹은 각각 독립적으로 H, C1-C6포화 또는 불포화 하이드로카빌, 또는 -(CH2)X-(Ar)-x[여기서, Ar은 페닐 또는 나프틸이고, x는 H, C1-C6알콕시, 할로겐 C1-C4알킬 또는 -S(O)XR1(여기서, x는 0,1또는 2의 정수이고, R1은 C1-C6알킬이다)이다]이다.
  4. 하기 일반식(I)또는 이의 약제학적으로 허용되는 염의 주효체 세포 상승 유효량을 이를 요하는 환자에 투여함을 특징으로 하여, 세포 면역계의 주효체 세포의 활성을 상승시키는 방법.
  6. 상기식에서, m은 3내지 12의 정수이고, z는 직쇄 또는 측쇄 배위의 포화 C2-C6알킬렌부위이며, R그룹은 각각 독립적으로 H, C1-C6포화 또는 불포화 하이드로카빌, 또는 -(CH2)X-(Ar)-x[여기서, Ar은 페닐 또는 나프틸이고, x는 H, C1-C6알콕시, 할로겐 C1-C4알킬 또는 -S(O)XR1(여기서,x는 0,1또는 2의 정수이고, R1은 C1-C6알킬이다)이다]이다.
  7. 제2항에 있어서, 상승된 주효체 세포(effector cell)가 T-세포인 방법.
  8. 제3항에 있어서, 상승된 주효체 세포가 천연의 세포-중재의 세포 독성 세포인 방법.
  9. 제2항에 있어서, 상승된 주효체 세포가 대식세포인 방법.
  10. 제1항 또는 2항에 있어서, 화합물이 3,7,15,19-테트라아자헨에이코산 테트라하이드로클로라이드인 방법.
  11. 제1항 또는 2항에 있어서, 2,17-디메틸-2,6,14,18-테트라아자노나데칸 테트라하이드로 클로라이드인 방법.
  12. 제1항또는 제2항에 있어서, 화합물이 4,16-디메틸-2,6,14,18-테트라아자노나데칸 테트라하이드로 클로라이드인 방법.
  13. 상승된 세포-중재의 면역성을 필요로 하는 환자치료용 약제를 제조하기 위한 하기 일반식(I)의 폴리아민 유도체 또는 이의 약제학적으로 허용되는 염의 용도.
  15. 상기식에서, m은 3내지 12의 정수이고, z는 직쇄 또는 측쇄 배위의 포화 C2-C6알킬렌부위이며, R그룹은 각각 독립적으로 H, C1-C6포화 또는 불포화 하이드로카빌, 또는 -(CH2)X-(Ar)-x[여기서, Ar은 페닐 또는 나프틸이고, x는 H, C1-C6알콕시, 할로겐 C1-C4알킬 또는 -S(O)XR1(여기서,x는 0,1또는 2의 정수이고, R1은 C1-C6알킬이다)이다]이다.
  16. ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019900007406A 1989-05-23 1990-05-23 폴리아민 유도체를 사용하여 세포- 중재의 면역성을 상승시키는 방법 Ceased KR900017577A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35573689A 1989-05-23 1989-05-23
US355736 1989-05-23

Publications (1)

Publication Number Publication Date
KR900017577A true KR900017577A (ko) 1990-12-19

Family

ID=23398633

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019900007406A Ceased KR900017577A (ko) 1989-05-23 1990-05-23 폴리아민 유도체를 사용하여 세포- 중재의 면역성을 상승시키는 방법

Country Status (11)

Country Link
EP (1) EP0399519B1 (ko)
JP (1) JP2835773B2 (ko)
KR (1) KR900017577A (ko)
AT (1) ATE141048T1 (ko)
AU (1) AU628174B2 (ko)
DE (1) DE69028006T2 (ko)
DK (1) DK0399519T3 (ko)
ES (1) ES2092481T3 (ko)
GR (1) GR3021500T3 (ko)
IE (1) IE81081B1 (ko)
ZA (1) ZA903804B (ko)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5561136A (en) * 1990-12-13 1996-10-01 Merrell Pharmaceuticals Inc. Method of treating cancer by conjunctive therapy with N,N'-bis[ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent
ZA919695B (en) * 1990-12-13 1992-09-30 Merrell Dow Pharma Method of treating cancer by conjunctive therapy with n,n'-bis(3-(ethylamino)propyl)-1,7-heptanediamine and a cytotoxic agent
GB9220921D0 (en) * 1992-10-05 1992-11-18 Merrell Dow Pharma Polyamine derivatives as anticytomegaloviral agents
SG49032A1 (en) * 1993-11-15 1998-05-18 Baker Med Res Inst A method for treating cardiac dysfunction and pharmaceutical compositions useful therefor
FR2724379B1 (fr) * 1994-09-13 1996-11-29 Fournier Sca Lab Procede de fabrication de polyamines qui sont des homologues structuraux de la spermidine.
US5516807A (en) * 1994-10-25 1996-05-14 Warner-Lambert Company Method for treating vascular proliferative disorders following balloon angioplasty
US7087648B1 (en) 1997-10-27 2006-08-08 The Regents Of The University Of California Methods for modulating macrophage proliferation using polyamine analogs
AU2003231670B2 (en) * 1997-10-27 2006-06-08 Slil Biomedical Corporation Methods for modulating macrophage proliferation using polyamine analogs
US8198334B2 (en) 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
RU2002128917A (ru) 2000-03-24 2004-03-10 Медиквест Терапевтикс, Инк. (Us) Полиаминные аналоги в качестве цитотоксических агентов
US6919483B2 (en) * 2003-05-23 2005-07-19 Mediquest Therapeutics, Inc. Immunomodulation with novel pharmaceutical compositions
JP7232845B2 (ja) * 2018-01-30 2023-03-03 パンベラ セラピューティクス インコーポレイテッド （６ｓ、１５ｓ）－３，８，１３，１８－テトラアザイコサン－６，１５－ジオールの製造方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5998015A (ja) * 1982-11-27 1984-06-06 Microbial Chem Res Found 免疫賦活剤
NZ212053A (en) * 1984-05-17 1988-02-29 Merrell Dow Pharma Polyamine containing pharmaceutical compositions for treating neoplasms
JPS62263127A (ja) * 1986-05-06 1987-11-16 メレルダウフア−マス−テイカルズ　インコ−ポレ−テツド 自己由来のｌａｋ細胞、インタ−ロイキン−２、及びオルニチンデカルボキシラ−ゼ阻害剤による腫瘍の処置
AU602186B2 (en) * 1987-02-03 1990-10-04 Merrell Dow Pharmaceuticals Inc. Novel polyamine derivatives

Also Published As

Publication number Publication date
EP0399519A3 (en) 1991-12-04
GR3021500T3 (en) 1997-01-31
JP2835773B2 (ja) 1998-12-14
IE81081B1 (en) 2000-02-23
IE901845L (en) 1990-11-23
AU5517190A (en) 1990-11-29
EP0399519B1 (en) 1996-08-07
JPH035420A (ja) 1991-01-11
AU628174B2 (en) 1992-09-10
DK0399519T3 (da) 1996-09-02
ES2092481T3 (es) 1996-12-01
DE69028006D1 (de) 1996-09-12
ATE141048T1 (de) 1996-08-15
ZA903804B (en) 1991-03-27
EP0399519A2 (en) 1990-11-28
DE69028006T2 (de) 1997-03-20

Similar Documents

Publication Publication Date Title
RU2218922C2 (ru) Соединения, имеющие в своей структуре фрагмент производного глюкуроновой кислоты и фрагмент производного глюкозамина, способы получения этих соединений и применение этих соединений
DK1140745T3 (da) Colchinolderivater som vaskulært skadelige midler
ES2295609T3 (es) Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor.
KR900701815A (ko) 피리미딘 유도체
KR900017577A (ko) 폴리아민 유도체를 사용하여 세포- 중재의 면역성을 상승시키는 방법
EA200200778A1 (ru) СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С В ОРГАНИЗМЕ ХОЗЯИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ПРОТИВ ФЛАВИВИРУСА, СОЕДИНЕНИЕ ФОРМУЛЫ Ib - АКТИВНЫЙ АГЕНТ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ИНФЕКЦИИ ГЕПАТИТА С ИЛИ ФЛАВИВИРУСА (ВАРИАНТЫ)
CY1111088T1 (el) Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση
CY1106634T1 (el) Θεραπευτικα παραγωγα της πιπεραζινης
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
MXPA02012730A (es) Uso de acido pamoico o uno de sus derivados o uno de sus analogos para la preparacion de un medicamento para el tratamiento de enfermedades caracterizadas por depositos de agregados de amiloide.
KR950701638A (ko) 푸린 동족체의 항비루스성 포스폰산 유도체(Antiviral phosphonic acid derivatives of purine analogues)
ES2148234T3 (es) Composicion farmaceutica a base de flavopereirina y su utilizacion en el tratamiento del virus vih.
KR930702985A (ko) 식도암의 치료
TW247876B (en) Pharmaceutical compositions for prevention or treating HIV-1 or HIV-2 infection
KR930702984A (ko) 비-소세포 폐암의 치료
AR005724A1 (es) Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple
RU2004116067A (ru) Фармацевтические композиции, содержащие макролиды
IL92586A (en) History of 5-hydroxy and 5-methoxy-2-aminopyrimidines as inhibitors of interleukin-1 formation
KR920019767A (ko) 티아졸 유도체
CA2167841A1 (en) Method of inhibiting the production of human immunodeficiency viruses with substituted azaspiranes
RU2219185C2 (ru) Новое полипептидное соединение
US20060063742A1 (en) Method of treatment for or protection against lymphedema
FR2455598A1 (fr) Nouveaux derives 5- (2- ((2,3-dihydro-1,4-benzodioxanne-2-ylmethyl)- amino)-1- hydroxyethyl)-2-hydroxybenzoiques, utiles notamment comme agents bloquants des recepteurs adrenergiques a et b, et leur procede de preparation
KR920011486A (ko) 항종양제
KR960703924A (ko) 항바이러스제로서 신규한 벤조티오펜 유사체(Novel Benzothiophene Analogs as Antiviral Agents)

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19900523

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19950522

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19900523

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19980319

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19980627

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19980319

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I